In a phase I clinical trial (NCT02016729), the MDM2 inhibitor AMG 232 achieved a 20% remission rate in patients with refractory acute myeloid leukaemia (AML) [16]. This evidence concerns the gene MDM2 and acute myeloid leukemia.